Casablanca slips 0.98% as TGCC jumps 82.4% and Taqa posts MAD 981 mln
The MASI fell 0.98% to 17,160.54 points on March 31, while the MASI 20 dropped 1.23% to 1,300.97 and the MASI Mid and Small Cap index lost 1.53% to 1,757.51. On earnings, TGCC reported an 82.4% jump in 2025 profit with a record order book, while operating income rose 53.4% to MAD 12.4 billion, according to Boursenews.ma and analyst notes. Taqa Morocco posted 2025 recurring net profit attributable to the group of MAD 981 million, down slightly according to lopinion.ma, while SNRTnews said the proposed dividend increased. Akdital, for its part, opened a new international expansion cycle and is scaling up, according to Boursenews.ma and L'Observateur, while CMGP Group's profit rose nearly 34% in 2025, Boursenews reported.
Related stories
MASI falls 0.83% as Label Vie and SMI post double-digit growth
The MASI fell 0.83% to 18,113.11 points on May 20, while the MASI 20 dropped 1.08% to 1,306.24 and the MASI Mid and Small Cap index lost 0.94% to 1,864.77. On the corporate front, Label Vie posted first-quarter 2026 revenue of 4.18 billion dirhams, up 15.9% at end-March, according to Le Matin.ma, Medias24 and L'Economiste. SMI reported a 36% jump in first-quarter revenue, driven by soaring silver prices, according to Medias24. Some stocks outperformed the weaker market, with AGM up 5.6% on May 20 after Promopharm gained 5.9% on May 19 and Unimer rose 6% to 167.45 dirhams on May 18, according to Casablanca Stock Exchange notes.
Casablanca Stock Exchange — AGM Jumps 5.6% Even as MASI Falls 0.83%
AGM posted one of the day’s standout gains on the Casablanca Stock Exchange, rising 5.6% to MAD 7,250 in a market dominated by declines. The MASI fell 0.83%, dragged by banks and industrial names, while a handful of mid-caps proved more resilient.
Casablanca Stock Exchange — Promopharm Jumps 5.9% Even as MASI Falls 1.0%
Promopharm posted the day’s best gain, rising 5.9% to MAD 1,346 while the MASI fell 1.0%. Mining losses and FX pressure drove the broader selloff, but pharmaceutical names showed unusual resilience.